News | Hypertension | October 04, 2018

Pulmonary Artery Denervation Significantly Improvements Hemodynamics in CpcPH

A randomized trial of pulmonary artery denervation in patients with combined pre- and postcapillary pulmonary hypertension

 Pulmonary artery denervation for CpcPH from the PADN-5 trial. #TCT2017

A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.


October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and clinical outcomes in patients with capillary pulmonary hypertension (CpcPH). This was the result of the late-breaking PADN-5 trial presented at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) symposium.

The randomized trial PADN in patients with combined pre- and post-capillary pulmonary hypertension was presented by Shao-Liang Chen, M.D., Division of Cardiology, Nanjing First Hospital Nanjing Medical University, Nanjing, China. PADN has been shown to improve hemodynamics of pulmonary arterial hypertension (PAH) in a series of patients. Additionally, benefits of targeted medical therapy in these patients for patients secondary to left sided heart failure was unknown. The objective was to assess the benefits of PADN among CpcPH patients in a prospective, randomized sham-controlled trial.

Ninety-eight CpcPH patients, defined as mean pulmonary arterial pressure ≥25 mmHg, pulmonary capillary wedge pressure >15 mmHg, and pulmonary vascular resistance (PVR] > 3.0 Woods Units, were randomly assigned to PADN or sildenafil plus sham PADN. Standard medical therapy for heart failure was administered to all patients in both groups. The primary endpoint was the increase in the 6-minute walk distance (6MWD) at the 6-month follow-up. The secondary endpoint was change in PVR. Clinical worsening was assessed in a post-hoc analysis. The main safety endpoint was occurrence of pulmonary embolism.

At six-months, the mean increases in the 6MWD were 83 m in the PADN group and 15 m in the sildenafil group (least square mean difference 66 m, 95% confidence interval 38.2 to 98.8; p < 0.001). PADN treatment was associated with a significantly lower PVR than in the sildenafil group (4.2 ± 1.5 vs. 6.1 ± 2.9 Wood Units, p = 0.001). Clinical worsening was less frequent in the PADN group compared to the sildenafil group (16.7% vs. 40%, p = 0.014). At the end of the study, there were 7 all-cause deaths and 2 cases of pulmonary embolism.

See the slides presented at TCT 2018 for this trial.

Find links to the TCT 2018 Late-breaking Cardiovascular Clinical Trials and Videos
 

 

 

Reference:

1. Hang Zhang, Juan Zhang, Mengxuan Chen, et al. Pulmonary Artery Denervation Significantly Increases 6-minute Walk Distance for Patients with Combined Pre- and Post-capillary Pulmonary Hypertension Associated with the Left Heart Failure: PADN-5 Study. JACC: Cardiovascular Interventions. September 2018. DOI: 10.1016/j.jcin.2018.09.021
 


Related Content

News | Hypertension

May 19, 2025 — Gradient Denervation Technologies recently announced the company’s pulmonary denervation system has ...

Home May 20, 2025
Home
News | Hypertension

April 9, 2025 — Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released ...

Home April 09, 2025
Home
News | Hypertension

Mar. 10, 2025-- Corcept Therapeutics Inc., a commercial-stage company engaged in the discovery and development of ...

Home March 11, 2025
Home
News | Hypertension

Jan. 9, 2025 — Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond ...

Home January 14, 2025
Home
News | Hypertension

Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines ...

Home January 08, 2025
Home
News | Hypertension

Dec. 11, 2024 — Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking ...

Home December 19, 2024
Home
News | Hypertension

June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative ...

Home June 28, 2024
Home
News | Hypertension

June 6, 2024 — A substantial portion of young athletes are at risk of hypertension, according to a study presented at ...

Home June 06, 2024
Home
News | Hypertension

May 16, 2024 — People were more likely to develop a type of treatment-resistant hypertension when they experienced ...

Home May 16, 2024
Home
News | Hypertension

May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. Bioelectronic medicine ...

Home May 08, 2024
Home
Subscribe Now